ES2537226T3 - Anticuerpos contra IL-25 - Google Patents

Anticuerpos contra IL-25 Download PDF

Info

Publication number
ES2537226T3
ES2537226T3 ES09795802.9T ES09795802T ES2537226T3 ES 2537226 T3 ES2537226 T3 ES 2537226T3 ES 09795802 T ES09795802 T ES 09795802T ES 2537226 T3 ES2537226 T3 ES 2537226T3
Authority
ES
Spain
Prior art keywords
gly
tyr
val
thr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09795802.9T
Other languages
English (en)
Spanish (es)
Inventor
David John Matthews
Jillian Barlow
Andrew Neil James Mckenzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Application granted granted Critical
Publication of ES2537226T3 publication Critical patent/ES2537226T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES09795802.9T 2008-09-30 2009-09-30 Anticuerpos contra IL-25 Active ES2537226T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10129308P 2008-09-30 2008-09-30
GB0817891 2008-09-30
GBGB0817891.5A GB0817891D0 (en) 2008-09-30 2008-09-30 Antibodies against il-25
US101293P 2008-09-30
PCT/IB2009/007302 WO2010038155A2 (fr) 2008-09-30 2009-09-30 Anticorps contre il-25

Publications (1)

Publication Number Publication Date
ES2537226T3 true ES2537226T3 (es) 2015-06-03

Family

ID=40019808

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09795802.9T Active ES2537226T3 (es) 2008-09-30 2009-09-30 Anticuerpos contra IL-25

Country Status (23)

Country Link
US (1) US8658169B2 (fr)
EP (1) EP2344538B1 (fr)
JP (1) JP5719771B2 (fr)
KR (1) KR101659452B1 (fr)
CN (1) CN102245638B (fr)
AU (1) AU2009299465B2 (fr)
BR (1) BRPI0919062A2 (fr)
CA (1) CA2739050C (fr)
CY (1) CY1116313T1 (fr)
DK (1) DK2344538T3 (fr)
ES (1) ES2537226T3 (fr)
GB (1) GB0817891D0 (fr)
HK (1) HK1154022A1 (fr)
HR (1) HRP20150524T1 (fr)
ME (1) ME02219B (fr)
MX (1) MX2011003351A (fr)
NZ (1) NZ592274A (fr)
PL (1) PL2344538T3 (fr)
PT (1) PT2344538E (fr)
RS (1) RS54028B1 (fr)
SI (1) SI2344538T1 (fr)
SM (1) SMT201500144B (fr)
WO (1) WO2010038155A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
EA031203B1 (ru) 2010-03-30 2018-11-30 Янссен Байотек Инк. Гуманизированные антитела к il-25
WO2013118878A1 (fr) * 2012-02-09 2013-08-15 独立行政法人理化学研究所 Arn cyclique et procédé d'obtention de protéine
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
CN107207589B (zh) * 2014-09-23 2021-04-06 瑞泽恩制药公司 抗il-25抗体及其使用方法
US11492397B2 (en) * 2016-03-16 2022-11-08 Abeome Corporation Neutralizing monoclonal antibodies to IL-25 and uses thereof
WO2018017864A2 (fr) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Agents de liaison à pvrig et leurs utilisations
WO2018018082A1 (fr) 2016-07-26 2018-02-01 The Australian National University Compositions immunostimulantes et utilisations de celles-ci
KR102598319B1 (ko) * 2018-11-19 2023-11-02 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 항-il-25 항체 및 그의 용도
GB202018015D0 (en) 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0276846A3 (fr) 1987-01-29 1989-07-26 Zymogenetics, Inc. Dérivés du facteur stimulant des colonies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2150262C (fr) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE517920T1 (de) 2003-04-23 2011-08-15 Medarex Inc Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
EP1863520B1 (fr) 2005-03-08 2014-12-31 Aptose Biosciences Inc. Utilisation de l'interleukine 17e pour le traitement du cancer
WO2007044450A2 (fr) 2005-10-06 2007-04-19 Baylor Research Institute Compositions et methodes pour le traitement du cancer
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
EA031203B1 (ru) * 2010-03-30 2018-11-30 Янссен Байотек Инк. Гуманизированные антитела к il-25
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
AU2009299465A1 (en) 2010-04-08
US20110250195A1 (en) 2011-10-13
JP2012503979A (ja) 2012-02-16
BRPI0919062A2 (pt) 2015-12-15
ME02219B (me) 2016-02-20
PT2344538E (pt) 2015-06-19
HRP20150524T1 (hr) 2015-08-14
KR20110086013A (ko) 2011-07-27
US8658169B2 (en) 2014-02-25
RS54028B1 (en) 2015-10-30
SI2344538T1 (sl) 2015-07-31
CY1116313T1 (el) 2017-02-08
CA2739050C (fr) 2018-05-29
DK2344538T3 (en) 2015-06-01
CA2739050A1 (fr) 2010-04-08
CN102245638B (zh) 2014-10-22
SMT201500144B (it) 2015-09-07
EP2344538B1 (fr) 2015-02-25
HK1154022A1 (en) 2012-04-13
JP5719771B2 (ja) 2015-05-20
AU2009299465B2 (en) 2012-07-26
EP2344538A2 (fr) 2011-07-20
MX2011003351A (es) 2011-05-25
PL2344538T3 (pl) 2015-10-30
CN102245638A (zh) 2011-11-16
NZ592274A (en) 2012-08-31
WO2010038155A2 (fr) 2010-04-08
WO2010038155A3 (fr) 2010-05-27
GB0817891D0 (en) 2008-11-05
KR101659452B1 (ko) 2016-09-23

Similar Documents

Publication Publication Date Title
ES2537226T3 (es) Anticuerpos contra IL-25
Cavaloc et al. Characterization and cloning of the human splicing factor 9G8: a novel 35 kDa factor of the serine/arginine protein family.
KR102236497B1 (ko) 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
KR101249607B1 (ko) 2가, 이중특이적 항체
EP3010931B1 (fr) Polypeptides f solubles et stabilisés du vrs en conformation pré-fusion
ES2799735T3 (es) Células de mamífero que expresan antígenos de citomegalovirus
WO2021189772A1 (fr) Protéines de fusion ace2-fc et leur utilisation
ES2869971T3 (es) Construcción de ácido nucleico
US20100098693A1 (en) Compositions and methods for blood-brain barrier delivery of organophosphatases
US20190338268A1 (en) Complement Factor B Analogs and Their Uses
KR20180026734A (ko) 안정화된 가용성 융합-전 rsv f 폴리펩티드
EP3579875A1 (fr) Anticorps anti-annexine a1 humaine
AU2011262494A2 (en) Fusion protein having factor VII activity
CN107074963B (zh) 抑制血管内皮脂肪酶的酶活性的人源化单克隆抗体
WO2018058088A1 (fr) Protéines de fusion améliorant la sécrétion associée à des cellules
ES2263626T3 (es) Peptidos lider para potenciar la secrecion de proteina recombinante a partir de una celula hospedante.
KR101342974B1 (ko) 신규 펩티드 태그 및 이의 용도
US20150175669A1 (en) Novel Peptide Tag and Uses Thereof
KR19990082185A (ko) 세포내 부동화 폴리펩티드 및 핵산
JP7028802B2 (ja) 短鎖型桿体由来錐体生存因子及び親水性ペプチド間の融合タンパク質
US20130071366A1 (en) Insulin-like growth factor ii (igf-ii) binding factors
Uitto et al. Structural relationship between DNA polymerases ε and ε⋆ and their occurence in eukaryotic cells
US20150191532A1 (en) Antibody For Epitope Tagging, Hybridoma Cell Line and Uses Thereof
JP4937570B2 (ja) 魚類による蛋白質の製造方法
KR101724614B1 (ko) 신규 카탈라아제 신호서열 및 이를 이용한 카탈라아제 발현방법